
Dell discusses an analysis of VOYAGE showing dupilumab more than doubled the odds of favorable asthma outcomes in children, regardless of baseline ICS dose.

Investigator, BC Children's Hospital
Head, Division of Respiratory Medicine, Department of Pediatrics, University of British Columbia
Professor, Department of Pediatrics, Faculty of Medicine, University of British Columbia